2021 global life science outlook

Patients are driving innovation:
- The patient is king:
  - Focused on individual needs
  - Patient-centric services

Government reimagines regulatory landscape:
- The new digital age of regulation
  - Post-COVID-19 regulatory landscape
  - Regulatory pathways for EUAs

Technological advancements:
- Technology changes everything:
  - Digital transformation
  - Cloud computing
  - Artificial intelligence

New ways of collaborating significantly reduce the
- Expanding access to new talent and new partners
- Strengthening management and review

Accelerated digitization:
- New points of care, new roles for pharma and medtech
- Redesigning work, workplace, and workforce, while meeting individual needs

Shortening development and review timelines:
- Thinking more like a regulator
- New customer-centric commercial model

Changes to drug development:
- Trials reshaping research & development
- New types of collaborations and clinical trials reshaping research & development

New customer-centric commercial model:
- New customer-centric commercial model
- Redesigning work, workplace, and workforce, while meeting individual needs

Top issues

Accelerated digitization: New points of care, new roles for pharma and medtech

Redesigning work, workplace, and workforce, while meeting individual needs

Shortening development and review timelines, thinking more like a regulator

New customer-centric commercial model

Cross-border reliance intensifies the need for:
- New types of collaborations and clinical trials reshaping research & development
- Accelerated digitization: New points of care, new roles for pharma and medtech
- Redesigning work, workplace, and workforce, while meeting individual needs
- Shortening development and review timelines, thinking more like a regulator
- New customer-centric commercial model

Regulation:
- Post-COVID-19 regulatory landscape
- Regulatory pathways for EUAs

Technology:
- Digital transformation
- Cloud computing
- Artificial intelligence

Collaboration:
- New types of collaborations and clinical trials reshaping research & development
- Accelerated digitization: New points of care, new roles for pharma and medtech
- Redesigning work, workplace, and workforce, while meeting individual needs
- Shortening development and review timelines, thinking more like a regulator
- New customer-centric commercial model

The Deloitte Touche Tohmatsu Limited's life sciences and health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss. Disclaimer